Literature DB >> 36009534

CK2 and the Hallmarks of Cancer.

May-Britt Firnau1, Angela Brieger1.   

Abstract

Cancer is a leading cause of death worldwide. Casein kinase 2 (CK2) is commonly dysregulated in cancer, impacting diverse molecular pathways. CK2 is a highly conserved serine/threonine kinase, constitutively active and ubiquitously expressed in eukaryotes. With over 500 known substrates and being estimated to be responsible for up to 10% of the human phosphoproteome, it is of significant importance. A broad spectrum of diverse types of cancer cells has been already shown to rely on disturbed CK2 levels for their survival. The hallmarks of cancer provide a rationale for understanding cancer's common traits. They constitute the maintenance of proliferative signaling, evasion of growth suppressors, resisting cell death, enabling of replicative immortality, induction of angiogenesis, the activation of invasion and metastasis, as well as avoidance of immune destruction and dysregulation of cellular energetics. In this work, we have compiled evidence from the literature suggesting that CK2 modulates all hallmarks of cancer, thereby promoting oncogenesis and operating as a cancer driver by creating a cellular environment favorable to neoplasia.

Entities:  

Keywords:  CK2; Casein kinase 2; cancer; hallmarks of cancer

Year:  2022        PMID: 36009534      PMCID: PMC9405757          DOI: 10.3390/biomedicines10081987

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  567 in total

1.  Regulation of the DNA binding of p53 by its interaction with protein kinase CK2.

Authors:  A Prowald; N Schuster; M Montenarh
Journal:  FEBS Lett       Date:  1997-05-12       Impact factor: 4.124

2.  Myosin-IIA heavy-chain phosphorylation regulates the motility of MDA-MB-231 carcinoma cells.

Authors:  Natalya G Dulyaninova; Reniqua P House; Venkaiah Betapudi; Anne R Bresnick
Journal:  Mol Biol Cell       Date:  2007-06-13       Impact factor: 4.138

3.  Protein kinase CK2 links extracellular growth factor signaling with the control of p27(Kip1) stability in the heart.

Authors:  Ludger Hauck; Christoph Harms; Junfeng An; Jens Rohne; Karen Gertz; Rainer Dietz; Matthias Endres; Rüdiger von Harsdorf
Journal:  Nat Med       Date:  2008-03-02       Impact factor: 53.440

4.  Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells.

Authors:  Karin Kohlstedt; Ralf P Brandes; Werner Müller-Esterl; Rudi Busse; Ingrid Fleming
Journal:  Circ Res       Date:  2003-11-13       Impact factor: 17.367

5.  The stability of CREB3/Luman is regulated by protein kinase CK2 phosphorylation.

Authors:  Beate Maria Schmitt; Emmanuel Ampofo; Heike Stumpf; Mathias Montenarh; Claudia Götz
Journal:  Biochem Biophys Res Commun       Date:  2020-01-12       Impact factor: 3.575

6.  Identification of casein kinase II phosphorylation sites in Max: effects on DNA-binding kinetics of Max homo- and Myc/Max heterodimers.

Authors:  K Bousset; M Henriksson; J M Lüscher-Firzlaff; D W Litchfield; B Lüscher
Journal:  Oncogene       Date:  1993-12       Impact factor: 9.867

7.  Casein kinase 2 (CK2) phosphorylates the deubiquitylase OTUB1 at Ser16 to trigger its nuclear localization.

Authors:  Lina Herhaus; Ana B Perez-Oliva; Giorgio Cozza; Robert Gourlay; Simone Weidlich; David G Campbell; Lorenzo A Pinna; Gopal P Sapkota
Journal:  Sci Signal       Date:  2015-04-14       Impact factor: 8.192

8.  CK2 phosphorylates and inhibits TAp73 tumor suppressor function to promote expression of cancer stem cell genes and phenotype in head and neck cancer.

Authors:  Hai Lu; Carol Yan; Xin Xin Quan; Xinping Yang; Jialing Zhang; Yansong Bian; Zhong Chen; Carter Van Waes
Journal:  Neoplasia       Date:  2014-10-23       Impact factor: 5.715

9.  Protein kinase CK2-dependent aerobic glycolysis-induced lactate dehydrogenase A enhances the migration and invasion of cancer cells.

Authors:  Dae-Kyun Im; Heesun Cheong; Jong Suk Lee; Min-Kyu Oh; Kyung Mi Yang
Journal:  Sci Rep       Date:  2019-03-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.